Peptide is one of those words that gets used loosely enough to stop meaning much. In the lab it has a precise definition, and the definition explains why these compounds behave the way they do in a model. This article starts at the amino acid and works up to receptor signaling, with no steps skipped.
Amino acids and the bond that links them
An amino acid has a central carbon carrying four things: an amino group, a carboxyl group, a hydrogen, and a side chain that makes it what it is. Twenty side chains appear in ordinary biological synthesis. Some are charged, some are greasy, some carry a ring, one has a sulfur that can form bridges.
A peptide bond forms when the carboxyl group of one amino acid condenses with the amino group of the next and a water molecule leaves. The resulting bond is an amide, and it is unusually rigid. Electrons delocalize across the carbonyl and the nitrogen, which gives the bond partial double-bond character and holds six atoms roughly in a plane. That rigidity is not a footnote. It is why chains fold into a limited set of shapes instead of flopping freely.
Two ends, one direction
A chain has a free amino group at one end and a free carboxyl group at the other. Those are the N-terminus and the C-terminus, and sequences are always written N to C. Biological synthesis also runs N to C, while solid-phase chemical synthesis runs the other way, building from the C-terminus while the chain is anchored to a resin. Our explainer on solid-phase synthesis covers why.
The termini are chemistry, not decoration. Many research peptides are modified at one end, often as an acetyl group on the N-terminus or an amide on the C-terminus, to remove a charge and slow enzymatic trimming. When a certificate lists a compound as amidated, that is what it means.
Where a peptide stops and a protein starts
The boundary is conventional rather than physical, but the convention is consistent enough to use.
| Term | Residue count | Typical example in research |
|---|---|---|
| Dipeptide, tripeptide | 2 to 3 | Short signaling fragments and bioregulator peptides |
| Oligopeptide | Roughly 4 to 20 | KPV at 3 residues sits below this; most melanocortin analogs sit inside it |
| Polypeptide | Roughly 20 to 50 | tesamorelin at 44 residues |
| Protein | Above roughly 50, often folded into a stable tertiary structure | Enzymes, antibodies, receptors |
The reason anyone draws the line at all is practical. Below about fifty residues a chain can usually be made by chemical synthesis and purified by chromatography. Above it, expression in cells becomes the realistic route, and the analytical work changes with it.
Sequence determines fold, and fold determines function
Given the rigid peptide bond, the only real freedom in the backbone is rotation around two angles per residue. Side chains then push and pull: hydrophobic residues bury themselves away from water, charged residues pair off, cysteines can form disulfide bridges that staple distant parts of the chain together.
Short peptides are usually flexible in solution and adopt a defined shape only when they meet their binding partner. Longer ones can hold a helix or a sheet on their own. Either way the biologically active surface is a small patch of side chains presented in a particular geometry, which is why a single substitution can change potency by orders of magnitude and why the exact sequence on a certificate matters more than the molecular weight.
How peptides signal in the published literature
Most peptides studied at the bench act from outside the cell. They bind a receptor in the membrane, commonly a G protein coupled receptor, and the binding event changes the receptor's shape. That change is transmitted inward, second messengers such as cyclic AMP or calcium rise or fall, kinases switch on, and transcription eventually shifts. The peptide itself never enters the cell.
Two features follow from this. Peptides are selective, because a large binding surface can discriminate between closely related receptors better than a small molecule can. And they are short lived, because circulating peptidases trim them and the kidney clears the fragments. Both features shape experimental design far more than potency does.
Natural, synthetic and analog
- Natural sequences occur in an organism. BPC-157 is described in the literature as a partial sequence of a protein found in gastric juice, and is studied for that reason.
- Synthetic peptides reproduce a natural sequence by chemistry rather than biology. The molecule is identical; the route is different.
- Analogs deliberately depart from the natural sequence. Substituting a D-amino acid for its natural L form, swapping a residue that peptidases recognize, cyclizing the chain, or attaching a fatty acid all serve the same goal, which is to keep the active surface while making the molecule harder to destroy.
Nearly every long-acting research peptide is an analog. The peptide catalog is mostly analogs for exactly this reason, and terms like amidated, lipidated and cyclic are defined in the research glossary.
Why peptides are studied at all
They occupy a middle ground. Small molecules are cheap and stable but often hit several targets. Antibodies are exquisitely selective but large, expensive and hard to get into tissue. Peptides sit between the two: selective enough to probe one receptor, small enough to synthesize to a known purity, and simple enough that a sequence change can be tested directly. For a laboratory asking what one receptor does in one model, that combination is hard to beat.
For a concrete example of how small sequence changes separate two analogs of the same parent hormone, see Melanotan-1 vs Melanotan-2, a linear and a cyclic analog of alpha-MSH.
Frequently asked questions
Is a peptide the same thing as a protein?
Chemically they are the same class of molecule, chains of amino acids joined by peptide bonds. The distinction is size and, by extension, how they are made and analyzed. Above roughly fifty residues the word protein is used.
Why do so many research peptides contain D-amino acids?
Peptidases evolved to recognize the natural L configuration. Substituting a D residue at a cleavage point slows enzymatic breakdown while often preserving the shape the receptor needs.
Does a higher molecular weight mean a more potent peptide?
No. Potency comes from how well the active surface fits its receptor. Some of the most potent peptides in the literature are short, and some long ones bind weakly.
References
- Nelson DL, Cox MM. Lehninger Principles of Biochemistry. Amino acids, peptides and proteins.
- IUPAC-IUB Joint Commission on Biochemical Nomenclature. Nomenclature and symbolism for amino acids and peptides.
- Merrifield RB. 1963. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. Journal of the American Chemical Society.
- Fosgerau K, Hoffmann T. 2015. Peptide therapeutics: current status and future directions. Drug Discovery Today.
- Lau JL, Dunn MK. 2018. Therapeutic peptides: historical perspectives and current development trends. Bioorganic and Medicinal Chemistry.
Research use only. This article is background biochemistry for laboratory researchers. Homegrown Peptides products are not for human or animal use, are not drugs, and are not intended to diagnose, treat, cure or prevent any disease. Nothing here is medical advice.
